Risankizumab for treating moderate to severe plaque psoriasis

Risankizumab (Skyrizi, AbbVie) has a marketing authorisation 'for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy'.

Risankizumab is administered by subcutaneous injection at a dose of 150 mg at weeks 0 and 4, and then every 12 weeks.

Consideration should be given to stopping treatment in people whose condition has shown no response after 16 weeks of treatment.

The list price of risankizumab is £3,326.09 per 150 mg dose (excluding VAT; price as quoted in company's submission).

The company has a commercial arrangement. This makes risankizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.